DE602006014535D1 - Verwendung von nt-proanp und nt-probnp zur diagnose von herzerkrankungen - Google Patents

Verwendung von nt-proanp und nt-probnp zur diagnose von herzerkrankungen

Info

Publication number
DE602006014535D1
DE602006014535D1 DE602006014535T DE602006014535T DE602006014535D1 DE 602006014535 D1 DE602006014535 D1 DE 602006014535D1 DE 602006014535 T DE602006014535 T DE 602006014535T DE 602006014535 T DE602006014535 T DE 602006014535T DE 602006014535 D1 DE602006014535 D1 DE 602006014535D1
Authority
DE
Germany
Prior art keywords
proanp
probnp
level
cardiac
increased level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006014535T
Other languages
English (en)
Inventor
Georg Hess
Andrea Horsch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics GmbH
Original Assignee
Roche Diagnostics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Diagnostics GmbH filed Critical Roche Diagnostics GmbH
Publication of DE602006014535D1 publication Critical patent/DE602006014535D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
DE602006014535T 2005-06-07 2006-06-07 Verwendung von nt-proanp und nt-probnp zur diagnose von herzerkrankungen Active DE602006014535D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05012196A EP1731910A1 (de) 2005-06-07 2005-06-07 Gebrauch von NT-proANP und NT-proBNP für die Diagnose von Herzkrankheiten
PCT/EP2006/062957 WO2006131529A1 (en) 2005-06-07 2006-06-07 Use of nt-proanp and nt-probnp for diagnosing cardiac diseases

Publications (1)

Publication Number Publication Date
DE602006014535D1 true DE602006014535D1 (de) 2010-07-08

Family

ID=34937270

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006014535T Active DE602006014535D1 (de) 2005-06-07 2006-06-07 Verwendung von nt-proanp und nt-probnp zur diagnose von herzerkrankungen

Country Status (8)

Country Link
US (1) US7608418B2 (de)
EP (2) EP1731910A1 (de)
JP (1) JP4828600B2 (de)
CN (1) CN101194167A (de)
AT (1) ATE469353T1 (de)
CA (1) CA2607264A1 (de)
DE (1) DE602006014535D1 (de)
WO (1) WO2006131529A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002218026A1 (en) 2000-11-09 2002-05-21 The Brigham And Women's Hospital, Inc. Cardiovascular disease diagnostic and therapeutic targets
DK2336359T3 (en) 2002-05-09 2016-05-30 Brigham & Womens Hospital 1L1RL-1 as cardiovascular disease marker
ES2344993T3 (es) * 2006-03-24 2010-09-13 F. Hoffmann-La Roche Ag Medios y metodos para la diferenciacion de la necrosis de miocardio aguda y cronica en pacientes sintomaticos.
PL2386860T4 (pl) 2006-04-24 2015-09-30 Critical Care Diagnostics Inc Przewidywanie śmiertelności i wykrywanie poważnej choroby
EP2482078B1 (de) 2006-05-01 2016-02-03 Critical Care Diagnostics, Inc. Diagnose von Herz-Kreislauf-Erkrankung
CN101611318B (zh) 2006-09-07 2015-03-04 奥塔哥创新有限公司 生物标记物
WO2008089994A1 (en) * 2007-01-25 2008-07-31 Roche Diagnostics Gmbh Use of igfbp-7 in the assessment of heart failure
EP1970709B1 (de) * 2007-03-06 2013-07-10 Roche Diagnostics GmbH Verwendung von Peptiden vom Typ BNP zur Vorhersage des Dialysebedarfs
DE102007010834A1 (de) * 2007-03-03 2008-09-04 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung von Herzinsuffizienz für NYHA I Patienten
DE102007022367A1 (de) * 2007-05-07 2008-11-20 B.R.A.H.M.S Ag Verfahren zur Bestimmung von aminoterminalen pro-ANP bei übergewichtigen Patienten
EP2210111A1 (de) * 2007-10-10 2010-07-28 Roche Diagnostics GmbH Natriuretisches peptid/troponin-verhältnis zur beurteilung bereits vorhandener myokard-fehlfunktion bei patienten mit akutem koronarsyndrom
WO2009047283A2 (en) 2007-10-10 2009-04-16 Roche Diagnostics Gmbh Means and methods for monitoring myocardial infarction and its treatment
EP2263086A4 (de) * 2008-02-22 2012-10-17 Otago Innovation Ltd Biomarker
CN101977933A (zh) 2008-03-12 2011-02-16 奥塔哥创新有限公司 生物标记物
CN102037014A (zh) 2008-03-12 2011-04-27 奥塔哥创新有限公司 生物标记物
DK2827152T3 (en) 2008-04-18 2016-09-12 Critical Care Diagnostics Inc PREDICTION OF RISK OF MAJOR ADVERSE HEART EVENTS
EP2318844A1 (de) * 2008-07-14 2011-05-11 Roche Diagnostics GmbH Multimarkerpanel zur diagnose, überwachung und auswahl der therapie für patienten mit herzinsuffizienz
US20110270530A1 (en) * 2008-12-08 2011-11-03 Seok-Won Lee Combined natriuretic peptide assays
BR112012011230A2 (pt) * 2009-11-13 2016-04-05 Bg Medicine Inc fatores de risco e previsão de infarto do miocárdio
EP2504705B1 (de) * 2009-11-27 2017-04-12 Roche Diagnostics GmbH Verfahren zur diagnose und überwachung von herzischämie bei patienten mit akutem brustschmerz und ohne myokardinfarkt
US20110306148A1 (en) 2010-06-14 2011-12-15 Siemens Healthcare Diagnostics Inc. Composition for use as an assay reagent
US9103840B2 (en) 2010-07-19 2015-08-11 Otago Innovation Limited Signal biomarkers
EP2686689B1 (de) 2011-03-17 2019-08-07 Critical Care Diagnostics, Inc. Verfahren zur vorhersage des risikos einer klinischen nebenwirkung
EP2737320B1 (de) * 2011-07-28 2016-08-24 B.R.A.H.M.S GmbH FRAGMENTE AUS DER MITTE DES PRO-NATRIURETISCHEN PEPTIDS VOM A-TYP (MR-proANP) ZUR IDENTIFIZIERUNG VON PATIENTEN MIT VORHOFFLIMMERN VON EINER DAUER VON WENIGER ALS 48 STUNDEN
WO2013053076A1 (en) * 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
EP3088900B1 (de) 2011-10-17 2020-08-12 Roche Diagniostics GmbH Troponin als marker für intermittierendes vorhofflimmern
EP2594940A1 (de) * 2011-11-16 2013-05-22 Koninklijke Philips Electronics N.V. Partikelabstoßung zur Verbesserung des Oberflächenkontakts in Magnetpartikelimmuntests
CA3081979C (en) * 2011-12-01 2023-07-11 F. Hoffmann-La Roche Ag Nt-proanp and nt-probnp for the diagnosis of stroke
WO2013141716A1 (en) 2012-03-20 2013-09-26 Christopher Joseph Pemberton Biomarkers
IN2015DN01767A (de) 2012-08-21 2015-05-29 Critical Care Diagnostics Inc
CN103304665A (zh) * 2013-05-21 2013-09-18 上海贝西生物科技有限公司 一种抗氨基末端脑利钠肽前体单克隆抗体及其应用
WO2015168145A1 (en) * 2014-04-28 2015-11-05 Penn Marc S Sdf-1 delivery for treating advanced ischemic cardiomyopathy
CN105085659B (zh) * 2014-05-20 2021-02-19 深圳大学 一种重组利钠肽及其制备方法
BR112020005682A2 (pt) * 2017-10-18 2020-10-20 Adrenomed Ag monitoração de terapia sob tratamento com um aglutinante de antiadrenomedulina (adm)
US12001939B2 (en) 2018-12-11 2024-06-04 Eko.Ai Pte. Ltd. Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views
US11446009B2 (en) 2018-12-11 2022-09-20 Eko.Ai Pte. Ltd. Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images
US11931207B2 (en) 2018-12-11 2024-03-19 Eko.Ai Pte. Ltd. Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR005600A0 (en) * 2000-09-12 2000-10-05 University Of Sydney, The Diagnostic assay
US6461828B1 (en) * 2001-09-04 2002-10-08 Syn X Pharma Conjunctive analysis of biological marker expression for diagnosing organ failure
MXPA03004105A (es) * 2002-05-14 2004-10-15 Hoffmann La Roche Elaboracion de una prognosis en casos de enfermedad cardiaca usando una combinacion de marcadores.
GB2403533A (en) * 2003-06-30 2005-01-05 Orion Corp Atrial natriuretic peptide and brain natriuretic peptide and assays and uses thereof
US7432107B2 (en) * 2005-01-24 2008-10-07 Roche Diagnostics Operations, Inc. Cardiac hormones for assessing cardiovascular risk
EP1859283A1 (de) * 2005-02-17 2007-11-28 F. Hoffmann-Roche AG Verwendung des nt-proanp/nt-probnp-verhältnisses zur diagnose von herzfehlfunktionen
CN101233411A (zh) * 2005-07-29 2008-07-30 皇家飞利浦电子股份有限公司 在心脏疾病的诊断、管理和治疗期间对心脏利钠肽的监视
PL2386860T4 (pl) * 2006-04-24 2015-09-30 Critical Care Diagnostics Inc Przewidywanie śmiertelności i wykrywanie poważnej choroby
EP1882945A1 (de) * 2006-07-28 2008-01-30 F.Hoffmann-La Roche Ag Vorrichtungen und Verfahren zur Differentierung zwischen herz- und lungenbedingten Ursachen für akute Atemnot
ATE449966T1 (de) * 2006-09-15 2009-12-15 Hoffmann La Roche Biochemische marker für akute lungenembolie
DE602006015964D1 (de) * 2006-09-20 2010-09-16 Roche Diagnostics Gmbh Natriurethische Peptide und Plazenta-Wachstumfaktor/löslicher VEGF-Rezeptor unterscheiden zwischen mit der Plazenta verbundener Herzdysfunktion und mit Herzerkrankung verbundener Herzdysfunktion
US9012151B2 (en) * 2006-11-09 2015-04-21 B.R.A.H.M.S. Gmbh Methods of diagnosis and risk stratification of adverse events in post myocardial infarction patients using pro-adrenomedullin

Also Published As

Publication number Publication date
US20090042228A1 (en) 2009-02-12
CA2607264A1 (en) 2006-12-14
WO2006131529A1 (en) 2006-12-14
ATE469353T1 (de) 2010-06-15
JP4828600B2 (ja) 2011-11-30
EP1731910A1 (de) 2006-12-13
EP1889073A1 (de) 2008-02-20
CN101194167A (zh) 2008-06-04
US7608418B2 (en) 2009-10-27
EP1889073B1 (de) 2010-05-26
JP2008542778A (ja) 2008-11-27

Similar Documents

Publication Publication Date Title
DE602006014535D1 (de) Verwendung von nt-proanp und nt-probnp zur diagnose von herzerkrankungen
ATE456055T1 (de) Diagnoseverfahren für erkrankungen im zusammenhang mit hirnschäden
DE602005002500D1 (de) Kombination von Markern für Diabetes Typ 1 und 2
Sheinerman et al. Early detection of neurodegenerative diseases: circulating brain-enriched microRNA
ATE537454T1 (de) Verfahren zum beurteilen von herzinsuffizienz bei patienten mit vorhofflimmern mittels gdf-15
RU2014145259A (ru) Прогнозирование нежелательных явлений у пациентов с предполагаемым диагнозом хронической сердечной недостаточности
Cai et al. Predictive value of phosphorylated axonal neurofilament subunit H for clinical outcome in patients with acute intracerebral hemorrhage
ATE483982T1 (de) Liquordiagnostisches in vitro verfahren zur diagnose von demenz-erkrankungen und neuroinflammatorischen erkrankungen
WO2009087190A1 (en) Means and methods for assessing the risk of patients presenting to emergency units based on gdf-15
ES2954321T3 (es) Proteína 3 de unión a ácidos grasos para la evaluación de fibrilación auricular (FA)
JP5715636B2 (ja) 循環系事象と虚血性事象を鑑別するためのＮＴ−ｐｒｏＡＮＰおよびＳＦｌｔ−１
JP2021156891A (ja) 軽度認知障害（ｍｃｉ）の診断、アルツハイマー病（ａｄ）型認知症の発症の予測、ならびにｍｃｉの処置または認知症発症の予防のための薬剤のスクリーニングおよびモニタリング
DE602006015964D1 (de) Natriurethische Peptide und Plazenta-Wachstumfaktor/löslicher VEGF-Rezeptor unterscheiden zwischen mit der Plazenta verbundener Herzdysfunktion und mit Herzerkrankung verbundener Herzdysfunktion
WO2008061978A3 (en) Means and methods for optimization of diagnostic and therapeutic approaches in chronic artery disease based on the detection of troponin t and nt-probnp
JP2009537797A (ja) 神経変性疾患の診断及び早期診断のためのｉｎｖｉｔｒｏ方法
Meyer et al. Plasma mid-regional pro-adrenomedullin levels are inversely associated with anxiety but unrelated to depression: Results from the observational DIAST-CHF study in patients with cardiovascular risk factors
ATE477329T1 (de) Verfahren zur detektion der in-vivo-aktivität von neurotrypsin, verwendung des verfahrens und verwendung des c-terminal 22-kda-fragments als biomarker bei der diagnose und überwachung von störungen im zusammenhang mit neurotrypsin
ES2657087T3 (es) Monitorización de péptidos natriuréticos cardiacos durante el diagnóstico, manejo y tratamiento de enfermedades cardiacas
CN103765219B (zh) 用于鉴定小于48小时之前发作的心房纤维性颤动患者的中段前心钠肽(pro‑ANP)
RU2755390C1 (ru) Способ диагностики дыхательной недостаточности при хронической обструктивной болезни легких
DE502004012230D1 (de) Verfahren zur diagnose von erkrankungen unter bestimmung von apolipoprotein c-i
ES2706539T3 (es) Método de diagnóstico in vitro de la Enfermedad de Alzheimer basado en el nivel redox de la albúmina en el líquido cefalorraquídeo
Hirons et al. P215 RFC1 disorder; a genetic, neuropathic cause of chronic cough
US20230176077A1 (en) Ret (rearranged during transfection) for the assessment of stroke
Digby et al. P216 Whole blood and plasma ATP levels in refractory/unexplained chronic cough

Legal Events

Date Code Title Description
8364 No opposition during term of opposition